GUILIN, CHINA - Media OutReach Newswire - 22 July 2026 - Known worldwide for its dramatic karst landscapes, Guilin has long been one of southern China's most iconic travel destinations. As travelers increasingly seek deeper connections with local communities, rural Guilin offers a different way to experience the countryside.

Here, visitors are not simply observers of the landscape - they become part of it, walking through rice terraces, cycling along rivers, tasting local cuisine, and discovering traditions that have evolved alongside nature for generations.

In the latest season of Village Voyage, CGTN host Julian Waghann from the United States and Filipino traveler Eliza Arce journey into Longsheng and Yangshuo, exploring how the mountains, rivers and people of Guilin continue to inspire a unique rural lifestyle.

Terraces shaped by generations of farming wisdom

Rising high in the mountains of Guangxi, the Longji Rice Terraces are far more than a spectacular agricultural landscape. Carved into the hillsides over centuries by generations of local communities, they embody a remarkable balance between human ingenuity and the natural world.

For local villager Liao Yanmei, the terraces are inseparable from everyday life. "They mean everything to us," she says. "They're our life." Today, she is leading efforts to restore and preserve the ancient terraces, ensuring this living heritage continues to thrive for generations to come.

Julian and Eliza arrive during the Shuyang Festival, one of Longsheng's most important annual farming celebrations. Walking along the narrow paths between the fields, they join villagers in the traditional seedling-throwing ritual and carry torches through the illuminated terraces as night falls.

For Eliza, the landscape evokes memories of the Banaue Rice Terraces in her native Philippines. "They're in the northern part of the country," she says. "They were also carved into the mountains by local communities. I was amazed by how closely our rice terrace cultures mirror each other. It made me realize we share deeper roots. And, in that moment, I truly felt at home."

Through these encounters, Julian and Eliza discover that the Shuyang Festival no longer marks only the beginning of the farming season. It has also become an immersive cultural experience, inviting visitors to step into the rhythms of rural life and discover a new way of experiencing China's countryside.

The secret behind the world's long hair village

Deep within the Longji Rice Terraces lies Huangluo Yao Village, home to the Red Yao people and renowned for its centuries-old long hair tradition. For generations, Red Yao women have cared for their famously long, glossy hair using fermented rice water, a natural hair treatment passed down from one generation to the next.

"Long hair, in Red Yao culture, symbolizes longevity and prosperity," said local cultural ambassador Haili. "We believe that healthy hair reflects a healthy body, bringing both long life and good fortune."

Drawing on generations of ecological knowledge, the Red Yao have long used rice water together with locally grown herbs to create a natural hair-care recipe. Rooted in the surrounding landscape, the tradition reflects a sustainable way of living that values natural resources and respects the rhythms of the environment.

Beyond their long hair tradition, the Red Yao are equally renowned for their exquisite costume craftsmanship. According to master artisan Pan Jifeng, completing a single traditional outfit can take an entire year. Weaving, batik, natural dyeing, and intricate embroidery come together in garments whose patterns are inspired by the mountains, animals, and everyday life, preserving generations of cultural memory.

Beyond the landscape: A new way to experience rural Guilin

While Guilin has long attracted visitors with its iconic scenery, a new generation of travelers is discovering the region through more immersive experiences.

In Yangshuo, the mountains and rivers have become a playground for outdoor exploration. Cycling through countryside paths, hiking among karst peaks, drifting along rivers on bamboo rafts, and experiencing cliffside adventures offer visitors a chance to engage with the landscape rather than simply admire it.

Supported by convenient transportation, diverse outdoor activities and growing tourism facilities, Yangshuo is emerging as an international destination where nature, culture and local life come together.

More than a journey: Villages connected by nature and culture

Every village tells its own story.

Some are written in the mountains, others in the rivers. Some live on through songs and festivals, while others survive through everyday traditions passed from one generation to the next.

From the rice terraces to the Karst landscapes, Guilin shows how rural communities continue to grow from the landscapes that shaped them - welcoming new visitors while keeping their own stories alive.

The issuer is solely responsible for the content of this announcement.

Hashtags: #CGTN #Guilin

Born from the synergy between fundamental research and industry, SURE is a project aimed at developing an Italian technology capable of making power supply for data centres more efficient and sustainable

ROME and GENOA, Italy, July 22, 2026 (GLOBE NEWSWIRE) -- Transmitting large quantities of electricity with no losses and minimal environmental impact. This is the challenge facing the SURE project, which combines the expertise of the National Institute of Nuclear Physics (INFN) and ASG Superconductors to develop a magnesium diboride (MgB₂) cable for next-generation data centres. The aim is to address one of the key challenges facing AI-driven digital infrastructure: reconciling growing power demand with efficiency and sustainability.

SURE (SUperconducting - REliability & Efficiency) stems from an agreement between ASG Superconductors and INFN, involving the INFN-LASA laboratory in Milan, which coordinates the project, and the INFN National Laboratories of Frascati. Funded by the Italian Ministry of University and Research through the Italian Fund for Applied Sciences (FISA), the initiative has a total budget of ?5.8 million and is expected to be completed by 2031. It includes the design, construction and installation of a superconducting power line for the new data centre at the INFN National Laboratories of Frascati.

At the core of the system is a magnesium diboride cable, a superconducting material discovered in 2001 and further developed by ASG through expertise gained in the CERN HiLumi-LHC programme. Unlike superconductors used in large particle accelerators, which require cooling to approximately 2 kelvin, MgB₂ operates at around 20 kelvin (-253?C), reducing cooling costs by more than ten times. This temperature can be maintained through closed-cycle cryogenic systems already used in industry. Thanks to superconductivity, electric current can be transmitted with virtually zero resistance, eliminating typical energy losses and enabling much higher power transmission within the same footprint.

The MgB₂ technology, developed and manufactured entirely in Italy by ASG Superconductors, does not require rare earth elements and is particularly suitable for cable applications thanks to the absence of heat dissipation and the simplicity of electrical connections. Superconducting cables can reduce space requirements by up to ten times compared with conventional technologies, optimizing infrastructure and improving long-term economic and environmental sustainability. Their compactness also creates new opportunities for data centres in urban areas or locations with infrastructure constraints.

Within the framework of SURE, ASG Superconductors and INFN will oversee the design, production and installation of a 50-metre prototype capable of carrying 1,500 A at 400 V. Researchers from the LASA laboratory in Milan and the INFN National Laboratories of Frascati will coordinate scientific activities and system integration, contributing to the development of future superconducting power grids for large-scale applications.

Luca Pezzoni

lpezzoni@hofima.it

+393389414437

Silvia Frigato Bonello

frigato.silvia@as-g.it

+390106489264

SURE: Pictures of MgB2 Superconducting zero losses energy transmission cable for data centre

A Media Snippet accompanying this announcement is available by clicking on this link.

Copyright 2026 GlobeNewswire, Inc.

JAKARTA, Indonesia, July 22, 2026 (GLOBE NEWSWIRE) -- PT Danantara Investment Management ("DIM"), through its subsidiary PT Daya Energi Bersih Nusantara ("Denera"), has opened registration for financing institutions to join a Lenders Panel for the Danantara Waste-to-Energy or Pengolahan Sampah Menjadi Energi Listrik (PSEL) Project, as Indonesia moves to accelerate investment in sustainable waste management infrastructure across multiple cities and/or regencies.

The panel is designed to create a diversified pool of prospective lenders and financing partners for a pipeline of PSEL projects across Indonesia. PT Indonesia Infrastructure Finance ("IIF") has been appointed as Financial Advisor to coordinate the lender registration and information-gathering process on behalf of DIM/Denera.

Through the Lenders Panel, DIM/Denera aims to identify financial institutions that possess financial strength, infrastructure financing experience and strategic interest to support PSEL program. The prospective lenders will be invited to indicate their financing appetite at both the portfolio and individual project levels, enabling DIM/Denera to assess potential financing capacity and explore suitable financing structures including sources of debt, non-cash facilities and other financing solutions prior to the commencement of any formal financing process.

The invitation is open to a broad range of financing institutions, including commercial banks, HIMBARA banks, Regional Development Banks/Bank Pembangunan Daerah (BPD), development finance institutions, multilateral institutions, export credit agencies and other financial institutions with the capability to provide, arrange, or support infrastructure financing.

Chief Financial Officer of Denera, M. Ramadhan Harahap (Idhan), stated "We invite financial institutions with an interest in and experience in infrastructure financing to participate in Denera's Lenders Panel. This initiative provides an opportunity for lenders to engage early in the development of financing solutions for PSEL projects, which will play a crucial role in transforming the country's waste management sector and advancing sustainable development objectives. We encourage prospective lenders to become part of this strategic initiative."

Participating institutions are invited to express their interest in offering or arranging senior loans, junior and subordinated loans, equity or equity-linked instruments, bridging loans, equity bridging facilities, bank guarantees, standby letters of credit, performance bonds, trade finance, mezzanine or hybrid structures, sustainability-linked financing, ECA- or MDB-supported financing, and other financing solutions relevant to the development and implementation of Indonesia's PSEL project pipeline.

Registration and Document Submission

Interested institutions may register their interest by contacting the official channel at lenderspanel.danantara@iif.co.id. IIF will guide prospective participants through the process, including the submission of the required information and execution of the applicable confidentiality arrangements. The document submission period will remain open until 28 July 2026.

Important Notice

This announcement is issued solely to invite expressions of interest for participation in the Lenders Panel. It is intended to facilitate market engagement and the collection of indicative information regarding financing capabilities and appetite. Participation in this process does not constitute, nor shall it be construed as, an offer, commitment, agreement, or obligation by DIM/Denera to enter into any financing arrangement, appoint any financing institution, or proceed with any transaction.

DIM/Denera reserves the right, at its sole discretion, to amend, suspend, postpone, or terminate the process, revise the timetable, request additional information, accept or reject any submission, or determine the composition of the Lenders Panel without incurring any liability to participating institutions. Each participating institution shall bear its own costs and expenses associated with its participation in this process. DIM/Denera shall not be liable for any costs, losses, or expenses incurred by any participant in connection with this process.

All information provided during the process will be treated as confidential and handled in accordance with the applicable Non-Disclosure Agreement (NDA).

For expressions of interest or request for clarification, interested institutions may contact:

PT Indonesia Infrastructure Finance (IIF)

Financial Advisor to DIM/DENERA

lenderspanel.danantara@iif.co.id.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6ecc285c-268e-4a54-904e-6724fcc07a9e

Copyright 2026 GlobeNewswire, Inc.

Supporting international entrepreneurs through Nevis company formation and offshore bank account opening within 24 to 48 hours

DUBAI, United Arab Emirates, July 22, 2026 (GLOBE NEWSWIRE) -- Trinity Group has entered into a strategic collaboration with Hamilton Reserve Bank to support international entrepreneurs and businesses, establishing a Nevis International Business Company (IBC) with a streamlined pathway from company formation to international banking.

Through the collaboration, eligible clients may establish an offshore bank account within 24 to 48 hours, subject to Hamilton Reserve Bank's independent onboarding procedures, customer due diligence and applicable regulatory requirements.

Nevis has earned international recognition as a respected jurisdiction for cross-border business, supported by its English common law heritage, modern corporate legislation and established international business environment. Increasingly, entrepreneurs and international businesses are choosing Nevis not only for company incorporation, but also for the integrated professional support that facilitates international business, including corporate advisory and international banking.

Trinity Group serves as the lead corporate adviser throughout the incorporation process, helping entrepreneurs and businesses establish Nevis corporate structures aligned with their commercial objectives. Combining international corporate advisory expertise with practical guidance on incorporation and ongoing administration, the firm supports clients at every stage of the Nevis company formation process.

Following incorporation, eligible clients requiring international banking services may be introduced to Hamilton Reserve Bank. Headquartered in Nevis, the Bank provides commercial, private and custodial banking, asset management and investment banking services through a digitally enabled multi-currency banking platform serving clients in more than 150 countries.

By connecting Nevis company formation with international banking, the collaboration creates a more efficient pathway for entrepreneurs establishing an international business. Rather than engaging separate providers for incorporation and banking, eligible clients benefit from a streamlined process while continuing to receive specialist corporate advice from Trinity Group and independently assessed banking services from Hamilton Reserve Bank.

* The collaboration is neither a merger, acquisition, joint venture nor exclusive partnership. Trinity Group and Hamilton Reserve Bank remain fully independent while combining their expertise to simplify Nevis company formation and access to international banking. Trinity Group provides corporate advisory and company formation services, while Hamilton Reserve Bank independently provides international banking services.

Media Enquiries

For media enquiries regarding this announcement, please contact:

Trinity Group

info@trinitygroup.eu

+971 4 447 8931

www.trinitycorporateservices.com

Copyright 2026 GlobeNewswire, Inc.

ISLAMABAD, July 22, 2026 (GLOBE NEWSWIRE) -- The Ministry of Information and Broadcasting (MOIB), which serves as the principal government body responsible for disseminating official communications including national budget announcements, issued the following statement today.

Finance Minister Muhammad Aurangzeb unveiled Pakistan's Rs 18.8 trillion federal budget for the fiscal year 2026?2027, which was influenced by global unrest. Earlier this year, the Iran-US war caused disruptions to the world's oil and LNG markets, driving up gas costs and straining a populace already burdened by inflation, a weak rupee, and tight health and education budgets. The final budget increased education investment and public health infrastructure, particularly cancer treatment and tertiary care, nationally, dispelling early concerns that health and education funding would be cut.

Steering Through Compounding Crises

The government cited internal fiscal strain, including debt servicing pressures and GDP growth of 3.7 percent, below target, as the backdrop for this budget in addition to the energy shock. Even as people paid more for fuel and utilities, officials characterised the year's diplomatic role in reducing regional tensions and new defence cooperation agreements as crucial to rebuilding investor confidence.

Taxation: Broad Relief, Sharper Enforcement

In addition to a 7% hike in salaries and pensions and a 10% increase in the minimum wage, the budget proposes income tax relief across four salaried-class slabs, lowering rates for individuals earning between Rs 600,000 and Rs 4.1 million annually by two to five points. The high-income earner surcharge is eliminated. The export surcharge and super tax burden have been reduced for exporters, and a new National Faceless Centre and algorithmic tax-settlement system are intended to reduce discretionary contact between taxpayers and officers.

Budget for Dignity: A Tax Cut That Empowers Women

One budget line deserves more attention: the administration removed the GST on contraceptive and menstrual hygiene products, which were formerly subject to the same 18% tax as other consumer goods. As part of the larger "pink tax" that women have long paid on health necessities, family planning and basic menstrual health items were formerly subject to the same tax burden as non-essentials. Whether something becomes available for a woman, a student, or a household already managing too many basic necessities can be determined by a tax exemption. This adjustment eliminates one financial barrier for a woman managing her health with dignity or a couple debating whether they can afford contraception.

Agriculture: Rebuilding the Economy's Backbone

A new Rs 7.1 billion Agri Storage Financing Facility to increase grain storage capacity for farmers, easier access to credit through interest-free digital loan schemes for smallholders, and ongoing rollout of electrification and rural livelihood programmes are all part of the budget's emphasis on agriculture as a growth priority.

Looking Ahead

The budget, which was developed through consultation with coalition partners, opposition input, and business community feedback, is described by the government as a foundation for stability rather than a completed journey with the goal of providing relief and growth to every household, farmer, and young worker nationwide.

Muhammad Subayyal

muhammad.subayyal@walee.pk

Copyright 2026 GlobeNewswire, Inc.

Investasi Enigmatig Bertujuan Mendukung Ambisi Kreatif Singapura untuk Berekspansi Lintas Negara

SINGAPURA, July 22, 2026 (GLOBE NEWSWIRE) -- Enigmatig Limited (NYSE American: EGG) ("Enigmatig" atau "Perusahaan"), perusahaan global yang memfasilitasi dan mendukung berbagai perusahaan berekspansi lintas negara, hari ini mengumumkan investasinya di KUNGFULAND.

Film ini merupakan film panjang komedi-aksi bernaskah pertama hasil produksi bersama Singapura dan Kanada berdasarkan perjanjian resmi yang menggunakan teknologi Produksi Virtual. Pengambilan gambar utama untuk film ini dimulai pada 10 Juni 2026 di AUX Infinite Studios, Singapura.

KUNGFULAND diproduksi oleh Ajacent Media yang berbasis di Singapura bersama 100 Dragons yang berbasis di Kanada, dengan dukungan Infocomm Media Development Authority (IMDA) Singapura. Berlatar di Chinatown pada tahun 1999, film ini menghadirkan penghormatan terhadap era keemasan film seni bela diri tahun 1970-an. Pengambilan gambarnya memadukan teknologi dinding LED mutakhir dengan perangkat praktis yang terinspirasi dari gaya Shaw Brothers. Film ini dibintangi oleh Idrissa Sanogo Bamba, Ellen Wong, Dion Johnstone, dan Hugh Tran, serta menampilkan cameo dari aktor legendaris Hong Kong, David Chiang.

"Di Enigmatig, pekerjaan kami selalu berpusat pada satu tujuan-membantu ide-ide ambisius berkembang melampaui batas negara. KUNGFULAND benar-benar mencerminkan semangat tersebut: sebuah kisah yang lahir di Singapura dan diciptakan untuk menjangkau dunia," ujar Desmond Foo, Pendiri sekaligus CEO Enigmatig.

"Kami bangga dapat mendukung produksi ini dan memberikan kontribusi kecil dalam membantu talenta kreatif lokal serta karya mereka menjangkau audiens yang lebih luas. Sebagai perusahaan yang berkantor pusat di Singapura, mendukung inisiatif seperti ini terasa berarti," tambahnya.

Bagi Enigmatig, investasi ini bukan sekadar investasi di industri film. Investasi ini mencerminkan keyakinan yang menggerakkan kegiatan inti Perusahaan-bahwa setiap ambisi layak mendapat dukungan, dari mana pun asalnya, dan bahwa Singapura memiliki beragam kisah yang layak dibagikan kepada dunia.

Naskah KUNGFULAND ditulis oleh Maninder Chana dari Kanada serta Jacen Tan dan Andrew Ngin dari Singapura, dengan Jacen Tan sebagai sutradara. Film ini akan diproduseri oleh Kat Goh dari Singapura dan Teresa M. Ho dari Kanada. Distribusinya akan ditangani oleh Shaw Organisation (Singapura), Raven Banner Releasing (Kanada), dan Flourishing Films (untuk wilayah lainnya di dunia).

Tentang Enigmatig Limited

Enigmatig adalah perusahaan global yang memfasilitasi dan mendukung berbagai perusahaan dalam mewujudkan ambisi internasional mereka. Sejak tahun 2010, kami telah menyediakan solusi regulasi, korporat, dan berbasis teknologi untuk membantu bisnis beroperasi dan menyesuaikan skalanya melintasi batas negara. Enigmatig yang berkantor pusat di Singapura, dengan kehadiran di Bangkok, Hong Kong, Jakarta, Shanghai, London, Taipei, dan Tokyo, melayani basis klien internasional yang beragam dan terus berkembang.

Untuk mengetahui informasi selengkapnya, kunjungi: https://enigmatig.com

Pernyataan Perlindungan Hukum

Pernyataan tertentu dalam pengumuman ini merupakan pernyataan berwawasan ke depan. Pernyataan berwawasan ke depan ini melibatkan risiko dan ketidakpastian yang diketahui maupun yang tidak diketahui, dan didasarkan pada ekspektasi serta proyeksi Perusahaan saat ini mengenai peristiwa masa depan yang diyakini Perusahaan dapat memengaruhi kondisi keuangan, hasil operasi, strategi bisnis, dan kebutuhan keuangannya. Investor dapat mengidentifikasi pernyataan berwawasan ke depan ini melalui kata atau frasa seperti "dapat," "bisa jadi," "akan," "seharusnya," "mungkin," "mengharapkan," "merencanakan," "bertujuan," "berniat," "mengantisipasi," "meyakini," "memperkirakan," "memprediksi," "kemungkinan akan," "potensial," "memproyeksikan" atau "melanjutkan" atau bentuk negatif dari istilah-istilah tersebut atau terminologi lain yang sebanding atau serupa. Perusahaan tidak memiliki kewajiban untuk memperbarui atau merevisi setiap pernyataan yang berwawasan ke depan untuk mencerminkan peristiwa atau keadaan yang terjadi kemudian, atau perubahan dalam ekspektasinya, kecuali sebagaimana dapat disyaratkan oleh hukum. Meskipun Perusahaan meyakini bahwa ekspektasi yang diungkapkan dalam pernyataan berwawasan ke depan ini bersifat wajar, Perusahaan tidak dapat menjamin bahwa ekspektasi tersebut akan terbukti benar, dan Perusahaan memperingatkan investor bahwa hasil sebenarnya mungkin berbeda secara signifikan dari hasil yang diperkirakan, dan mengimbau investor untuk meninjau faktor-faktor lain yang dapat memengaruhi hasilnya di masa mendatang dalam pernyataan pendaftaran Perusahaan dan dokumen lainnya yang diserahkan ke SEC, yang tersedia untuk ditinjau di www.sec.gov.

Untuk pertanyaan dari investor dan media, silakan hubungi:

investors@enigmatig.com / cindy@enigmatig.com

Copyright 2026 GlobeNewswire, Inc.

BANGKOK, THAILAND - Media OutReach Newswire - 22 July 2026 - At the Nikkei Asia Forum APAC 2026, Mr. Thammasak Sethaudom, President and Chief Executive Officer of SCG, shared his vision that the transition toward a low-carbon economy is no longer solely an environmental challenge, but a business strategy to strengthen long-term competitiveness through energy security, innovation, and sustainable growth.

He emphasized that stronger regional collaboration will help position ASEAN as a resilient and competitive hub for manufacturing, innovation, and sustainable growth.

During the panel discussion, Thammasak noted that geopolitical uncertainty continues to reshape global supply chains and energy markets, directly affecting production costs and industrial competitiveness. He stressed that the transition to clean energy should be viewed not only as a sustainability agenda but also as a strategic approach to strengthening economic resilience and long-term competitiveness.

He highlighted ASEAN's strong potential to lead the energy transition, supported by abundant renewable resources, including solar, wind, and bioenergy. Unlocking this potential, however, requires closer collaboration between governments and businesses to accelerate energy infrastructure, enable investment, and create an ecosystem that supports innovation and low-carbon industries.

Thammasak also underscored the importance of investing in innovation, Artificial Intelligence (AI), automation, and low-carbon technologies to improve productivity, optimize energy use, and enhance industrial competitiveness across the region.

Drawing on SCG's experience, he cited low-carbon cement as an example of how sustainability can create business value. When green products deliver comparable quality and competitive pricing, customers are more willing to adopt them, accelerating the transition toward a low-carbon economy.

"The transition toward a low-carbon society can become a reality only when sustainability is not an option for a few, but an opportunity that all sectors can access and benefit from together."

This vision reflects SCG's Business Purpose, Inclusive Green Growth, which integrates economic growth, environmental responsibility, and social well-being through innovation and collaboration, creating shared value and supporting a more sustainable future for ASEAN.

The issuer is solely responsible for the content of this announcement.

Hashtags: #SCG

Pilot Kobe Welcomes Little Travellers Onboard - 47% Savings and Family‑Friendly Perks

HONG KONG, July 22, 2026 (GLOBE NEWSWIRE) -- Dorsett Kai Tak, Hong Kong's newest family‑friendly hotel located beside the landmark Kai Tak Sports Park, invites families to "take off" on a memorable summer journey with its Fantastic 4 Family Summer Staycation package, offering 47% savings for family rooms. This season, little travellers will be welcomed by Pilot Kobe Teddy and a brand‑new mini luggage box*, making every stay feel like the start of an exciting adventure.

Ready for Take Off: Family Comforts Await

Families can save up to 47% while enjoying spacious family rooms, thoughtful kids' amenities, and complimentary breakfast. Room options include the Family Quad Studio (accommodating up to 5), Triple Room, Family Quad Room, and Premier Interconnecting Rooms.

Each stay comes with a Thoughtful Kids' Amenity Bag featuring slippers and toothbrush, a "Little Foodies" snack box, and Kobe Teddy as welcome gifts. Children will also discover hidden sweet treats in‑room, while parents traveling with babies can request complimentary baby gear rentals. For added excitement, *families booking the Family Quad Studio will receive a Dorsett Kai Tak limited-edition mini luggage box - the perfect travel companion for little explorers to begin their journey in style.

Premier Triple Room

Premier Interconnecting Room (Harbour View Subject to Availability)

Premier Triple Room Premier Interconnecting Rooms

Guests will enjoy free access to the rooftop infinity pool and the flexibility of a 26‑hour stay (e.g. check in at 4 PM, check out at 6 PM the next day) - by booking direct.

Rain or shine, families can explore indoor kid‑friendly attractions such as Joypolis, Epicland, and JUST CLIMB Climbing Wall, all within a 10‑minute walk. With complimentary shuttle service to AIRSIDE mall and Kai Tak MTR, the city is at your doorstep - just four stops away from Tsim Sha Tsui, where endless family attractions await.

BOOK DIRECT at the official Dorsett Kai Tak website to save up to 47% for a family‑friendly staycation in Hong Kong's newest landmark destination.        

About Dorsett Kai Tak, Hong Kong

This flagship property of Dorsett Hospitality International, conveniently located near Kai Tak Sports Park, provides exclusive stadium access and a complimentary shuttle to AIRSIDE and Kai Tak MTR.

Guests can choose from 373 stylish rooms and suites and enjoy an infinity pool, 24‑hour gym, Jin Bo Law Skybar, and dining at Kai Fuk Lau and Siete Ocho.

Media Contact

Ms. Felicity CHEUNG felicity.cheung@dorsetthotels.com

Media Image Library

Copyright 2026 GlobeNewswire, Inc.

Expansion at this facility is required to meet the rising demand for high-voltage, LFP battery systems for the rail industry.

Gateshead, U.K., July 22, 2026 (GLOBE NEWSWIRE) -- Driven by demand from Hitachi Rail, following the recent production milestone, and the growth of hybrid rail operations globally, Turntide Technologies (Turntide) is expanding its high-voltage lithium-iron-phosphate (LFP) rail battery systems manufacturing line to the Turntide Sunderland facility.

The high-voltage battery system enables hybrid and tri-mode trains to operate on both electrified and non-electrified rail lines while reducing fuel consumption and emissions.

This LFP battery system allows for lower cost of operations, extended range, and a path to zero-emission travel, while reducing reliance on fossil fuels and improving air quality and noise pollution. It will be manufactured exclusively at the Sunderland location. This battery production is an advanced manufacturing milestone for Arriva's Grand Central new fleet, which is being built by Hitachi Rail in Newton Aycliffe, County Durham. 

"The global rail industry is moving quickly toward hybrid and tri-mode platforms as operators look for practical ways to reduce emissions, improve efficiency, and extend the reach of electrified rail networks," Steve Hornyak, CEO, Turntide, said. "Our continued collaboration with Hitachi Rail reflects the strength of this market demand and the confidence in Turntide's high-voltage LFP battery technology.

"Expanding production at Sunderland gives us the capacity, capability, and operational focus to support this next phase of growth while helping accelerate cleaner, more flexible rail transportation."

The Sunderland facility provides the manufacturing space and testing capabilities to support Turntide's growing production of LFP battery systems. Paul Turbitt, senior director of strategic operations at Turntide, will oversee the Sunderland facility and this manufacturing expansion.

To learn more about battery hybrid rail, register for the August Current & Wave webinar, Hybrid Rail Solutions for the Next Era of Electrified Mobility.

About Turntide

Turntide Technologies designs and manufactures best-in-class electric motors, power electronics, and energy storage for anything that moves.

Turntide Technologies operates in North America, the U.K., and India and serves customers in global markets and industries including off highway automotive, commercial vehicles, rail, marine, light vehicles, and premium automotive.

Contact Info

Lori Ditoro

Lori.ditoro@turntide.com

+44 191 497 9000

Attachment

The Turntide Facility in Sunderland, U.K.

Copyright 2026 GlobeNewswire, Inc.

Peran Amerika Latin yang semakin meningkat dalam industri real estat global mendorong kebutuhan akan koneksi lintas negara yang lebih kuat, keahlian lokal, dan kemitraan yang tepercaya

BELLINGHAM, Washington, July 22, 2026 (GLOBE NEWSWIRE) -- eXp Realty, "the most agent-centric real estate brokerage on the planet" dan anak perusahaan utama AGNT, Inc. (Nasdaq: AGNT), hari ini mengumumkan informasi lebih lanjut mengenai eXpcon Medell?n yang akan digelar pada tanggal 6?8 April 2027.

Acara ini akan menjadi eXpcon pertama yang diselenggarakan di Amerika Latin sekaligus yang pertama kali digelar sepenuhnya dalam bahasa Spanyol. Penyelenggaraan acara ini menegaskan semakin pentingnya kawasan Amerika Tengah, Amerika Latin, dan Karibia (CALA) dalam jaringan global eXp.

Seiring meningkatnya minat pembeli dari Amerika Serikat dan Kanada terhadap peluang di luar pasar domestik, baik untuk investasi properti, hunian kedua, maupun relokasi, kemampuan dalam menangani transaksi lintas negara serta membangun kemitraan lokal yang tepercaya menjadi semakin penting. eXp Realty saat ini beroperasi di delapan pasar di kawasan CALA: Brasil, Cile, Kolombia, Republik Dominika, Ekuador, Meksiko, Peru, dan Puerto Riko. eXpcon Medell?n mempertemukan para agen dengan ahli pasar dari berbagai negara di Amerika Latin untuk memperkuat koneksi tersebut serta membantu mereka melayani klien dengan lebih baik dalam mencapai tujuan real estat yang melampaui pasar domestik mereka.

"Kawasan CALA menaungi sejumlah agen paling gigih dan berjiwa wirausaha di seluruh jaringan kami," ujar Felix Bravo, Managing Director eXp International. "Perbedaan antara pasar real estat lokal dan internasional semakin tidak terlihat. Para agen kami semakin sering melayani klien yang memiliki tujuan real estat di lebih dari satu kota atau negara. Menghadirkan eXpcon di Amerika Latin dan membawakannya sepenuhnya dalam bahasa Spanyol merupakan investasi untuk membekali para agen dengan pengetahuan, koneksi, dan keahlian pasar yang mereka perlukan untuk menghadapi masa depan."

Bagi para agen di seluruh Amerika Utara dan kawasan lainnya, eXpcon Medell?n menawarkan kesempatan unik untuk merasakan langsung salah satu kawasan real estat paling dinamis di dunia. Acara ini dirancang untuk membantu peserta memahami pasar yang sedang berkembang dengan lebih baik, memperkuat jaringan rujukan, serta menemukan peluang baru untuk melayani klien yang memiliki minat terhadap real estat di berbagai wilayah Amerika Latin.

"Peran Amerika Latin dalam real estat global terus meningkat," ujar Virginia Restrepo, CALA Regional Director di eXp International. "Selama bertahun-tahun, para agen kami telah berkeliling dunia untuk belajar dari banyak orang. Kini giliran kami menyambut dunia ke Amerika Latin serta memperkenalkan inovasi, keahlian, dan semangat kewirausahaan yang membentuk masa depan industri real estat di seluruh pasar kami. Penyelenggaraan eXpcon sepenuhnya dalam bahasa Spanyol memastikan setiap percakapan terasa autentik bagi masyarakat serta komunitas yang mendorong momentum tersebut."

Konferensi selama tiga hari ini akan menghadirkan pembicara utama, sesi edukasi bisnis dan kepemimpinan, peluang berjejaring, serta program yang dirancang khusus untuk kawasan tersebut, yang seluruhnya disampaikan dalam bahasa Spanyol.

Pendaftaran awal dengan harga khusus kini telah dibuka melalui expconintl.exprealty.com. eXplorer Pass juga tersedia bagi agen di luar eXp yang ingin merasakan langsung model kolaboratif perusahaan.

Tentang AGNT, Inc. (AGNT)

Built by Agents. Built for Agents (Dibangun oleh Agen. Dibangun untuk Agen). AGNT, Inc. (Nasdaq: AGNT) adalah perusahaan induk global dari eXp Realty, "the most agent-centric real estate brokerage on the planet"; NextHome, Inc., waralaba real estat nasional peraih penghargaan; FrameVR.io, platform kolaborasi virtual; serta SUCCESS? Enterprises, merek terkemuka di bidang pengembangan diri dan media bagi wirausahawan. Secara keseluruhan, platform AGNT menghadirkan sistem operasi multi-model berkelas dunia yang mendukung agen independen, pemilik waralaba, dan pemimpin tim di kawasan Amerika, Eropa, Timur Tengah, Asia Pasifik, dan Afrika Selatan. Sebagai perusahaan terbuka, AGNT, Inc. memprioritaskan transparansi, inovasi, dan nilai jangka panjang bagi para agen, pemilik waralaba, karyawan, dan pemegang saham.

Pernyataan Berwawasan ke depan dan Tindakan Perlindungan

Siaran pers ini berisi pernyataan berwawasan ke depan dalam artian Private Securities Litigation Reform Act tahun 1995. Pernyataan ini mencerminkan ekspektasi Perusahaan dan manajemennya saat ini, tetapi melibatkan risiko dan ketidakpastian yang diketahui dan tidak diketahui yang dapat memengaruhi hasil aktual secara signifikan. Pernyataan-pernyataan ini termasuk, namun tidak terbatas pada, pernyataan mengenai eXpcon Medell?n, ekspansi berkelanjutan Perusahaan di kawasan CALA, serta perkiraan waktu pelaksanaan, program, dan manfaat acara tersebut.

Faktor-faktor penting yang dapat menyebabkan hasil aktual berbeda secara signifikan dan berdampak merugikan dari yang dinyatakan dalam pernyataan berwawasan ke depan mencakup kemampuan Perusahaan untuk menarik dan mempertahankan agen serta memperluas jaringannya di kawasan CALA dan pasar internasional lainnya; risiko yang terkait dengan beroperasi di yurisdiksi asing, termasuk fluktuasi mata uang, ketidakstabilan politik dan ekonomi, serta perbedaan persyaratan peraturan atau hukum; fluktuasi pasar real estat secara umum; perubahan peraturan; serta risiko lainnya yang dari waktu ke waktu dijelaskan dalam dokumen yang diserahkan Perusahaan kepada Komisi Sekuritas dan Bursa AS (SEC), termasuk namun tidak terbatas pada Laporan Triwulanan di Formulir 10-Q dan Laporan Tahunan di Formulir 10-K yang terakhir disampaikan. Kami tidak memiliki kewajiban apa pun untuk memperbarui pernyataan ini kecuali sebagaimana diwajibkan oleh hukum.

Kontak Hubungan Media:

AGNT, Inc.

mediarelations@agnt.inc

Kontak Hubungan Investor:

Denise Garcia

investors@agnt.inc

Copyright 2026 GlobeNewswire, Inc.

SHANGHAI, July 21, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental application for toripalimab in combination with platinum-containing chemotherapy as perioperative treatment and subsequent monotherapy as adjuvant therapy for the treatment of adult patients with resectable stage II-III non-small cell lung cancer (NSCLC) has been accepted by the National Medical Products Administration (NMPA). The supplemental application expands toripalimab's indication from adult patients with resectable stage IIIA-IIIB NSCLC to adult patients with resectable stage II-III NSCLC.

Lung cancer is a malignant tumor with the highest prevalence and mortality rate in the world. According to data released by the National Clinical Research Center for Cancer, in 2024, there were approximately 1.18 million new lung cancer cases and 0.74 million lung cancer deaths in China, accounting for 22.83% of all new cancer cases and 28.79% of all cancer deaths in the nation. Amongst these cases, 20%-25% were surgically resectable at first diagnosis, but even after radical surgical treatment, 30%-55% of the patients suffered from post-surgical recurrence and death. Radical surgery in combination with chemotherapy is one way to prevent recurrence, but chemotherapy, as preoperative neoadjuvant or postoperative adjuvant therapy, has limited clinical benefits and can only improve the 5-year survival rate by around 5%.

Immunotherapy, with PD-(L)1 inhibitors at the forefront, has been transforming the landscape of cancer treatment. It has long-term effects in terms of tumor control and/or elimination by relieving the immune suppression of tumor cells and reactivating the patients' own immune cells to kill cancer. Many local and international lung cancer treatment guidelines recommend PD-(L)1 inhibitors as one of the standard perioperative treatments for resectable stage II-III NSCLC.

The supplemental application is principally based on NEOTORCH (NCT04158440), a randomized, double-blind, placebo-controlled phase 3 clinical study aiming to compare the efficacy and safety of toripalimab or placebo in combination with chemotherapy as perioperative treatment for resectable stage II/III NSCLC patients. Led by principal investigator Professor Shun LU of Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, the study enrolled a total of 501 patients with resectable stage II-III NSCLC. The primary endpoints are event-free survival (EFS) in patients with stage III and stage II-III disease as assessed by researchers, and major pathological response (MPR) rate in patients with stage III and stage II-III disease as assessed by the Blind Independent Pathology Review Committee (BIPR). The secondary endpoints include overall survival (OS), EFS as assessed by the Independent Review Committee (IRC), pathological complete remission rate (pCR rate), disease-free survival (DFS) and safety.

In January 2023, the EFS interim analysis of patients with resectable stage III NSCLC of NEOTORCH met the primary endpoint. The study results were presented through oral presentation at the April 2023 session of the American Society of Clinical Oncology (ASCO) Plenary Session and the 2023 ASCO Annual Meeting. NEOTORCH was the world's first phase 3 clinical study of an anti-PD-1 monoclonal antibody for NSCLC perioperative treatment (including neoadjuvant and adjuvant) with positive EFS results published in the Journal of the American Medical Association (JAMA) in January 2024.

The results showed that compared to perioperative chemotherapy alone, toripalimab in combination with chemotherapy as perioperative treatment led to a significant improvement in EFS (median EFS: not reached vs. 15.1 months, P<0.001), reduced risk of disease recurrence, progression events or death by 60% (HR=0.40, 95% CI: 0.28-0.57). Meanwhile, the OS in the toripalimab in combination with chemotherapy group showed a clear trend toward improved outcomes (HR=0.62, 95% CI: 0.38-1.00). Moreover, toripalimab in combination with chemotherapy as perioperative treatment increased the pCR rate to nearly 25-fold (pCR rate: 24.8% vs. 1.0%) and the MPR rate to nearly 6-fold (MPR rate: 48.5% vs. 8.4%).

In December 2023, based on the NEOTORCH interim analysis results, the supplemental new drug application for the new indication of toripalimab in combination with platinum-containing doublet chemotherapy for perioperative treatment of resectable stage IIIA-IIIB NSCLC patients was approved by the NMPA. It was the first domestically approved perioperative therapy for lung cancer in China, and the second worldwide.

In May 2026, the NEOTORCH finished the final analysis. The primary endpoints of EFS and MPR rate in the stage II-III population, as well as the MPR rate in the stage III population, met the pre-defined efficacy boundary.

In July 2026, the full results of a post hoc analysis of surgical outcomes from the NEOTORCH of toripalimab in combination with chemotherapy for perioperative treatment of resectable stage III NSCLC patients were officially published in JAMA Surgery, a leading international journal in the field of surgery. The analysis focused on stage III NSCLC patients who underwent surgery in the NEOTORCH and systematically evaluated the effects of toripalimab in combination with chemotherapy as perioperative treatment on surgical feasibility, complications, survival and other outcomes.

The results demonstrated that toripalimab in combination with chemotherapy significantly reduced the surgery cancellation rate (17.8% vs. 26.7%; p=0.03), thereby enabling more patients to undergo surgical resection without increasing perioperative risks or giving rise to any new safety signals. Among the 314 patients who completed surgery, compared with placebo in combination with chemotherapy, toripalimab in combination with chemotherapy effectively achieved higher rates of tumor downstaging and lymph node downstaging (tumor downstaging rate: 80.7% vs. 50.7%, lymph node downstaging rate: 67.5% vs. 48.6%), and improved the EFS benefit of the patients (HR=0.50, 95% CI: 0.33-0.74; p＜0.001). Among the patients who achieved tumor downstaging or lymph node downstaging, toripalimab in combination with chemotherapy significantly improved EFS compared with placebo in combination with chemotherapy (HR=0.45 for both, p=0.002 and p=0.009).

About Toripalimab

Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and to induce PD-1 receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system's ability to attack and kill tumor cells.

More than forty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Europe and Southeast Asia. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types, including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney, and skin.

In the Chinese mainland, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI). Currently, there are twelve approved indications for toripalimab in the Chinese mainland:

unresectable or metastatic melanoma after failure of standard systemic therapy;

recurrent or metastatic nasopharyngeal carcinoma (NPC) after failure of at least two lines of prior systemic therapy;

locally advanced or metastatic urothelial carcinoma (UC) that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy;

in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC;

in combination with paclitaxel and cisplatin in first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic esophageal squamous cell carcinoma (ESCC);

in combination with pemetrexed and platinum as the first-line treatment in EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC);

in combination with chemotherapy as perioperative treatment and subsequently with monotherapy as adjuvant therapy for the treatment of adult patients with resectable stage IIIA-IIIB NSCLC;

in combination with axitinib for the first-line treatment of patients with medium to high risk unresectable or metastatic renal cell carcinoma (RCC);

in combination with etoposide plus platinum for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC);

in combination with paclitaxel for injection (albumin-bound) for the first-line treatment of recurrent or metastatic triple-negative breast cancer (TNBC);

in combination with bevacizumab for the first-line treatment of unresectable or metastatic hepatocellular carcinoma (HCC) patients;

first-line treatment for unresectable or metastatic melanoma;

in combination with disitamab vedotin for the first-line treatment of HER2-expressing UC.

The first 12 indications have been included in the National Reimbursement Drug List (NRDL) (2025 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for the treatment of melanoma, RCC and TNBC. Toripalimab for the treatment of advanced NPC and ESCC was approved in Hong Kong SAR, China.

Internationally, toripalimab has been approved for marketing in nearly 50 countries and regions including the United States, the European Union, India, the United Kingdom, Australia, Singapore, Malaysia and South Africa, and is also under review for marketing in various countries and regions worldwide.

About Junshi Biosciences

Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. With our outstanding capacity for innovative drug discovery, strong biotechnology R&D capability, and large-scale production capacity, we have successfully developed a drug candidate portfolio with global competitiveness and a well-structured research pipeline, which covers therapeutic areas including cancer, autoimmune, metabolic, and infectious diseases. Our innovative field spans cutting-edge therapeutic modalities, including mAbs, small-molecule drugs, ADCs, bsAb/msAb, fusion proteins, nucleic acid drugs and vaccines. Five of the company's products have received marketing authorizations in China and international markets, one of which is toripalimab, China's domestically developed anti-PD-1 monoclonal antibody. Toripalimab has been approved in nearly 50 countries and regions including China, the US, and Europe.

With a mission of "providing patients with world-class, trustworthy, affordable, and innovative drugs," Junshi Biosciences is "In China, For Global." At present, the company boasts nearly 3,000 employees mainly in the United States (Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou). For more information, please visit: http://www.junshipharma.com.

Junshi Biosciences Contact Information

IR Team:

Junshi Biosciences

info@junshipharma.com

+ 86 021-6105 8800

PR Team:

Junshi Biosciences

Zhi Li

zhi_li@junshipharma.com

+ 86 021-6105 8800

Copyright 2026 GlobeNewswire, Inc.

RIYADH, Arab Saudi, July 21, 2026 (GLOBE NEWSWIRE) -- Keputusan seorang ayah untuk mendonorkan sebagian organ hatinya demi menyelamatkan anak laki-lakinya telah menjadi terobosan medis pertama. King Faisal Specialist Hospital and Research Centre (KFSH) telah berhasil melakukan transplantasi hati pertama di dunia dengan menggunakan sistem robotik port tunggal pada seorang anak laki-laki berusia enam tahun yang berulang kali mengalami episode gagal hati akut.

Pencapaian ini membawa bedah robotik minimal invasif melangkah lebih jauh, menembus salah satu bidang tersulit dan paling menuntut ketelitian dalam dunia transplantasi organ anak.

Transplantasi ini terwujud berkat sang ayah yang mendonorkan lobus kiri hatinya. Keputusan itu membawa secercah harapan baru bagi keluarga yang telah lama bergelut dengan kecemasan menghadapi penyakit sang anak. Prosedur berlangsung dengan lancar, ditandai dengan pemulihan awal sang anak yang baik, cangkok hati berfungsi dengan baik, serta tidak ditemukan adanya komplikasi.

Pasien mengidap sindrom Wolcott-Rallison, sebuah kelainan bawaan langka yang menyebabkan diabetes dengan awitan dini serta episode gagal hati akut yang berulang. Kondisi ini berkali-kali menempatkannya dalam risiko yang mengancam nyawa.

Transplantasi ini mengatasi komplikasi paling serius dari penyakit tersebut, membuka jalan bagi sang anak untuk menjalani hidup yang lebih stabil sekaligus meringankan beban medis dan emosional yang selama ini ditanggung dirinya bersama keluarga. Dia akan terus dipantau secara berkelanjutan, baik untuk kelainan genetik yang menjadi akar penyakitnya maupun diabetes yang menyertainya.

Sistem robotik port tunggal memungkinkan dokter bedah memasukkan instrumen bedah presisi dan kamera 3D beresolusi tinggi melalui satu sayatan kecil, berbeda dengan bedah robotik multi-port konvensional yang membutuhkan beberapa titik akses. Melalui satu port inilah tim bedah menjalankan tahap-tahap tersulit dari transplantasi di dalam tubuh mungil sang anak. Area bedah yang sempit ini menuntut penanganan pembuluh darah dan saluran empedu dengan tingkat presisi yang luar biasa tinggi. Pendekatan ini pun membantu mengurangi dampak pembedahan, meredakan nyeri, serta mempersingkat masa pemulihan dan lama rawat inap.

Prof. Dieter Broering, Direktur Eksekutif Organ Transplant Center of Excellence sekaligus pemimpin tim bedah, mengatakan bahwa keberhasilan prosedur semacam ini tidak hanya bergantung pada ketersediaan teknologi, melainkan pada pemilihan pasien yang cermat, perencanaan bedah yang teliti, dan tim yang berpengalaman di setiap tahap transplantasi. Ia menuturkan bahwa nilai sejati dari sebuah inovasi bedah terletak pada pemanfaatan teknologi untuk meringankan beban pasien beserta keluarga mereka, dengan tetap menjunjung standar keselamatan tertinggi.

Tahapan pencapaian ini meneruskan langkah perintis yang dimulai KFSH sejak tahun 2023 melalui transplantasi hati pertama di dunia yang dilakukan sepenuhnya dengan robot. Sejak saat itu, upaya tersebut berkembang menjadi sebuah program terpadu dengan 165 kasus yang telah dilakukan hingga kini, didukung oleh lebih dari 1.700 reseksi hati robotik dari donor hidup. Akumulasi keahlian ini mencerminkan kemampuan KFSH dalam mengubah pencapaian bersejarah menjadi program klinis yang maju. Program semacam inilah yang benar-benar mengubah jalan hidup sebuah keluarga. Tak hanya itu, keberhasilan ini turut memperluas penggunaan robotik dalam bedah transplantasi yang sangat kompleks, sekaligus memperkuat posisi Arab Saudi dalam inovasi medis dan keunggulan layanan kesehatan.

King Faisal Specialist Hospital and Research Centre menempati peringkat pertama di Timur Tengah dan Afrika serta peringkat ke-12 dunia di antara 250 pusat medis akademik terkemuka dunia untuk tahun 2026. Rumah sakit ini juga diakui sebagai merek layanan kesehatan paling bernilai di Kerajaan Arab Saudi dan Timur Tengah untuk tahun 2026 oleh Brand Finance, serta masuk dalam daftar Newsweek sebagai World's Best Hospitals, World's Best Smart Hospitals, dan World's Best Specialized Hospitals untuk tahun 2026.

Untuk informasi selengkapnya, kunjungi www.kfshrc.edu.sa atau hubungi tim media kami di mediacoverage@kfshrc.edu.sa

Foto yang menyertai pengumuman ini tersedia di https://www.globenewswire.com/NewsRoom/AttachmentNg/f717fac0-6fc6-4f96-add8-64cc956115c9

Copyright 2026 GlobeNewswire, Inc.

VICTORIA, Seychelles, July 21, 2026 (GLOBE NEWSWIRE) -- Bitget, the world's largest Universal Exchange (UEX), has emerged as one of the leading venues for TradFi trading products, generating nearly $70 billion in TradFi perpetual trading volume in Q2 2026, according to the TokenInsight Q2 2026 Crypto Exchange Report.

The report cements Bitget's growing presence in the rapidly expanding TradFi segment, where crypto exchanges are increasingly connecting digital asset infrastructure with global financial markets.

The report found that TradFi perpetuals became one of the fastest-growing segments across crypto exchanges during Q2, with monthly trading volume increasing from $52 billion in January to $268 billion in June. Equity perpetuals became the main growth driver during the quarter as exchanges expanded into tokenized stocks, IPO products, and other real-world assets. TokenInsight noted that TradFi perpetuals have evolved from an emerging product category into a strategically important area of competition for exchanges.

Bitget's growth in TradFi markets follows a series of product launches under its Universal Exchange strategy, including IPO Prime and Stocks 2.0, which were highlighted by TokenInsight among the industry's notable Q2 developments. The report also found that TradFi perpetuals accounted for 8.61% of Bitget's total derivatives volume, the second-highest penetration rate among major centralized exchanges.

During the quarter, Bitget maintained a top-three position across both commodity and equity perpetual markets, while recording nearly $70 billion in TradFi perpetual trading volume. The exchange also expanded its broader derivatives position, with futures open interest market share increasing from 7.81% in Q1 to 8.58% in Q2, marking one of the strongest gains among major exchanges tracked by TokenInsight.

"The data points to a market that is starting to catch up with the vision behind our Universal Exchange," said Gracy Chen, CEO of Bitget. "UEX is built around the belief that investors don't want separate platforms for crypto and traditional finance, they want frictionless access to opportunities across both. The trading volumes we're seeing today reinforces that this is where the market is heading."

The findings come as the broader exchange industry shifts toward multi-asset trading. While total crypto exchange volume declined modestly to $16.5 trillion in Q2, spot activity recovered from $3.3 trillion to $4.5 trillion as market participants responded to renewed volatility and Bitcoin's repeated tests of the $60,000 support level.

Bitget's Universal Exchange ecosystem brings together crypto, tokenized equities, commodities, and other global assets through a unified trading experience. As TradFi and crypto markets continue to converge, Bitget continues expanding the infrastructure needed to support increasingly diverse trading activity.

Read TokenInsight's Q2 2026 Crypto Exchange Report here.

Copyright 2026 GlobeNewswire, Inc.

VICTORIA, Seychelles, July 21, 2026 (GLOBE NEWSWIRE) -- Bitget, the world's largest Universal Exchange (UEX), today announced a collaboration with Siebly.io, a provider of professional-grade API SDKs for algorithmic traders and developers, to simplify integration with Bitget's V3 Unified Trading Account and V2 Classic APIs.

The collaboration gives developers access to the Bitget SDK by Siebly, enabling faster, more reliable connectivity across Bitget's spot, futures, copy trading, and real-time market data infrastructure.

Developers and algorithmic traders increasingly rely on stable API tooling to build, test, and deploy trading systems. However, fragmented API environments, inconsistent client libraries, and complex migration paths can slow down development and introduce operational risk. By working with Siebly, Bitget is helping developers reduce integration complexity while supporting both its new Unified Trading Account architecture and existing V2 Classic workflows.

Siebly.io provides ready-made developer tools that help trading teams connect to crypto exchanges without building every API connection from scratch. For developers and algorithmic traders, especially those built with JavaScript and TypeScript, they can connect to Bitget faster, reduce technical errors, and spend more time building trading strategies, bots, and market data tools instead of managing complex API integrations.

"UEX is about delivering a better trading experience for users and developers worldwide independent of the assets they trade," said Gracy Chen, CEO of Bitget. "Collaborating with Siebly makes it easier to build reliable tools across Bitget's unified account architecture, helping traders spend less time on integration and more time building strategies on Bitget."

Siebly's SDKs provide comprehensive coverage across Bitget's ecosystem, including spot trading, futures trading, copy trading, public market data streams, and private account management. For latency-sensitive strategies, the SDK also supports WebSocket API functionality, allowing developers to execute REST-like request-response patterns over a persistent connection and reduce request overhead without the added complexity of managing WebSockets manually.

The SDK also includes built-in support for HMAC, RSA, and Ed25519 authentication, helping developers securely interact with Bitget's infrastructure while maintaining flexibility across different authentication standards. With consistent development patterns across supported exchanges, Siebly's tooling is designed to help developers move between platforms with less friction and shorter implementation cycles.

"Developers building automated trading systems need SDKs that are consistent, secure, and tested in production environments," said Tiago Siebler, Lead Developer at Siebly.io. "By collaborating with Bitget, we are making it easier for developers to integrate with one of the industry's leading trading ecosystems."

Bitget's UEX framework is strengthened with this collaboration by improving the infrastructure layer that connects developers, trading systems, and Bitget's unified account environment. By making API access more efficient across spot, futures, copy trading, and real-time data, Bitget continues to expand the tools available to retail and professional developers building the next generation of crypto trading applications.

For media inquiries, please contact: media@bitget.com 

Risk Warning: Digital asset prices are subject to fluctuation and may experience significant volatility. Investors are advised to only allocate funds they can afford to lose. The value of any investment may be impacted, and there is a possibility that financial objectives may not be met, nor the principal investment recovered. Independent financial advice should always be sought, and personal financial experience and standing carefully considered. Past performance is not a reliable indicator of future results. Bitget accepts no liability for any potential losses incurred. Nothing contained herein should be construed as financial advice. For further information, please refer to our Terms of Use.

Copyright 2026 GlobeNewswire, Inc.

SINGAPURA, July 21, 2026 (GLOBE NEWSWIRE) -- Zoom Communications, Inc. (NASDAQ: ZM) hari ini mengumumkan pengangkatan Carlos Quaderi sebagai Kepala Asia Pasifik (APAC), yang berlaku efektif mulai 1 Agustus 2026. Pengangkatan ini menegaskan investasi berkelanjutan perusahaan di APAC sebagai kawasan pertumbuhan strategis.

Pengangkatannya dilakukan saat berbagai organisasi di seluruh APAC mulai beralih dari alat produktivitas yang berdiri sendiri menuju sistem berteknologi AI yang mengurangi kompleksitas, menghubungkan alur kerja, dan membantu tim bergerak lebih cepat dari sekadar percakapan hingga pekerjaan selesai.

Dengan melapor langsung kepada Graeme Geddes, Chief Sales and Growth Officer Zoom, Quaderi akan memimpin strategi go-to-market (peluncuran produk) Zoom di seluruh APAC, yang mencakup Australia dan Selandia Baru (ANZ), Asia, India, serta Korea, tidak termasuk Jepang.

Sebelumnya, Quaderi menjabat sebagai Kepala Zoom Asia, dengan tugas menjalankan strategi regional, eksekusi penjualan, serta berbagai inisiatif go-to-market untuk Asia Tenggara, Daerah Administratif Khusus Hong Kong, dan Taiwan. Kini beliau akan mengawasi wilayah APAC yang lebih luas, dengan bekerja sama erat bersama tim regional dan jajaran pimpinan global untuk menjalankan prioritas strategis perusahaan, dengan fokus pada bisnis pengalaman pelanggan (customer experience/CX), segmen usaha kecil dan menengah (UKM), serta pengembangan kanal.

Sebagai profesional senior dengan pengalaman lebih dari 30 tahun di industri, Quaderi sebelumnya pernah menduduki berbagai posisi kepemimpinan senior di Workday, Amazon Web Services, dan Microsoft. Dalam berbagai peran tersebut, beliau memimpin strategi go-to-market serta pertumbuhan segmen enterprise di kawasan Asia Pasifik dan Jepang. Quaderi akan tetap berbasis di Singapura dan terus mengawasi bisnis Zoom di Asia selama masa transisi.

"APAC merupakan kawasan pertumbuhan yang sangat penting, dan investasi berkelanjutan kami mencerminkan besarnya peluang di segmen enterprise dan UKM, bisnis pengalaman pelanggan (CX), serta ekosistem mitra kami," ujar Geddes. "Carlos telah berperan penting dalam membangun momentum pertumbuhan kami, dan memperluas cakupan kepemimpinannya merupakan langkah selanjutnya yang wajar. Pemahamannya yang mendalam tentang kawasan ini, fokus yang kuat pada pelanggan, serta rekam jejaknya akan membantu lebih banyak organisasi mengoptimalkan kemampuan AI Zoom untuk meningkatkan produktivitas, memperkuat hubungan dengan pelanggan, dan mempercepat pertumbuhan bisnis."

"Di seluruh APAC, tim bekerja lebih cepat dari sebelumnya dan membutuhkan teknologi yang mampu mengimbangi kecepatan tersebut tanpa menghilangkan sentuhan manusia maupun momentumnya," ujar Quaderi. "Saya antusias dapat bekerja bersama pelanggan dan mitra kami di kawasan ini untuk membantu mereka membuka peluang baru melalui sistem tindakan berteknologi AI dan ekosistem terbuka Zoom. Dengan menghubungkan percakapan, orang, dan alur kerja, mereka dapat mempercepat proses mengubah ide menjadi dampak nyata serta mencapai hasil bisnis yang bermakna."

Zoom terus meningkatkan investasinya di kawasan APAC dengan memperluas ekosistem mitra dan membuka kantor baru di Singapura. Dengan terintegrasi ke berbagai aplikasi bisnis yang telah digunakan, ekosistem platform terbuka Zoom membantu organisasi meningkatkan kolaborasi, mempererat hubungan antarmanusia, dan menghadirkan pengalaman pelanggan yang lebih baik melalui kemudahan dan keandalan yang menjadi ciri khas Zoom.

Tentang Zoom

Zoom (NASDAQ: ZM) adalah sistem tindakan untuk dunia kerja modern, yang mengubah kolaborasi secara langsung menjadi pekerjaan yang terselesaikan. Mulai dari wirausahawan hingga perusahaan global, pelanggan memilih Zoom untuk berkolaborasi dan berkomunikasi dengan lancar serta mencapai hasil yang diharapkan melalui rapat, telepon, pusat kontak, dan layanan lainnya, yang semuanya didukung oleh bantuan Zoom AI bawaan. Didirikan pada tahun 2011, Zoom berkantor pusat di San Jose, CA. Untuk mengetahui informasi selengkapnya, kunjungi zoom.com.

Humas Zoom

Hayley Yap

press@zoom.us 

Copyright 2026 GlobeNewswire, Inc.

VICTORIA, Seychelles, July 21, 2026 (GLOBE NEWSWIRE) -- Bitget, the world's largest Universal Exchange (UEX), has launched the industry's first TradFi Quanto Perpetual Futures, a new derivative market structure which enables trading of non-USD-denominated stocks using USDT without any currency conversion.

The first contract, MINIMAXHKDUSDT, tracks Hong Kong-listed AI company MiniMax and is live today with up to 20x leverage only on Bitget.

The contract prices the underlying stock in its local currency, HKD for Hong Kong equities or JPY for Japanese equities, but settles margin, funding fees, and realized P&L entirely in USDT. The system treats the local-currency price as numerically equivalent to USDT at 1:1, so the contract's price movement matches the underlying stock exactly, without any fiat involvement.

"Quanto contracts are not new in crypto derivatives, but no major exchange has applied the structure to traditional financial assets until now," said Gracy Chen, CEO at Bitget. "From Pre-IPO access to US stock options, we are building a trading environment where crypto infrastructure serves global financial markets. The Quanto contracts remove the last barrier for global traders: currency conversion. Anyone holding USDT can now trade Hong Kong and other non-USD stocks as easily as they trade Bitcoin. This is convergence in practice which Bitget has been able to crack."

The problem the product solves is straightforward. A user who wants to buy Hong Kong stocks in HKD normally has to convert USDT to HKD first, taking on exchange rate risk on both the position and the conversion itself. Bitget's quanto structure removes that step. A trader opening a long position of 10 MINIMAXHKDUSDT contracts at 30 and closing at 50 earns 200 USDT, calculated as (50 minus 30) times 10, settled directly to the futures account. No forex conversion happens at any point.

The launch lands in a market that is growing fast. TokenInsight's Crypto Exchange Report Q2 2026 found that TradFi perpetuals were the fastest-growing segment across the crypto exchange industry in the quarter. Monthly volume expanded from roughly $52 billion in January to $268 billion in June, a fivefold increase over the first half of the year, with equity perpetuals overtaking commodities as the primary growth driver. Bitget was one of the fastest-growing platforms in the sector. The exchange generated approximately $69 billion in TradFi perpetual volume during Q2, capturing 11.01% market share and ranking second among all exchanges.

The quanto launch follows a year of product firsts that have made TradFi a core part of Bitget's business rather than a side feature. The exchange introduced tokenized stock perpetual contracts offering synthetic exposure to publicly traded companies with USDT settlement and up to 100x leverage, then added CFD trading in late 2025 for access to global equities, commodities, and forex through stablecoin settlement. In April 2026, Bitget launched IPO Prime, the industry's first Pre-IPO trading service, powered by Republic, giving users exposure to private companies such as SpaceX before public listing. In July, Bitget became the only major crypto exchange offering US stock options, with long call and long put strategies on US-listed equities alongside crypto and CFD markets.

The MINIMAXHKD Quanto Perpetual Contracts is now live on Bitget and supports up to 20x leverage, 24/7 trading, and funding rate settlement every 8 hours. To know more visit here.

About Bitget

Bitget is the world's largest Universal Exchange (UEX), serving over 125 million users and offering access to over 2M crypto tokens, 500+ tokenized stocks, ETFs, commodities, FX, and precious metals such as gold. The ecosystem is committed to helping users trade smarter with its AI agent, which co-pilots trade execution. Bitget is driving crypto adoption through strategic partnerships such as MotoGP?. Aligned with its global impact strategy, Bitget has joined hands with UNICEF to support blockchain education for 1.1 million people by 2027. Bitget currently leads in the tokenized TradFi market, providing the industry's lowest fees and highest liquidity across 150 regions worldwide.

For more information, visit: Website | X | Telegram | LinkedIn | Discord

For media inquiries, please contact: media@bitget.com

Risk Warning: Digital asset prices are subject to fluctuation and may experience significant volatility. Investors are advised to only allocate funds they can afford to lose. The value of any investment may be impacted, and there is a possibility that financial objectives may not be met, nor the principal investment recovered. Independent financial advice should always be sought, and personal financial experience and standing carefully considered. Past performance is not a reliable indicator of future results. Bitget accepts no liability for any potential losses incurred. Nothing contained herein should be construed as financial advice. For further information, please refer to our Terms of Use.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/886dfb0b-711a-4231-9cb4-29d5710d3ec1

Copyright 2026 GlobeNewswire, Inc.

New Video Showcases the Younger Generation's Journey from Campus into the World of TCM

Pitch Notes:

Beijing Tong Ren Tang (BTRT, 3613.HK) just released a new video showcasing its "Student Ambassador Programme for Chinese Medicine and Health Care."

The initiative bridges BTRT's 350-year heritage with innovation to make Traditional Chinese Medicine (TCM) relevant for Hong Kong primary and secondary students.

Quick Story Angles:

Innovation: Students explore TCM delivery via 5G technology.

Modern Appeal: Hands-on learning in daily herbal wellness.

Preventive Care: Youth adopting the core principle of "preventive treatment of disease."

You can view the full video with student sharing directly via this YouTube Link: https://youtu.be/6LRyk_DLucA.

The attached press release provides deeper project details. Would this fit an upcoming health, education, or local news feature?

Thank you!

To learn more about the students' journey of discovery, please click the link below to watch the programme video on BTRT's YouTube: https://youtu.be/6LRyk_DLucA

HONG KONG SAR - Media OutReach Newswire - 21 July 2026 - Beijing Tong Ren Tang Chinese Medicine Company Limited ("BTRT") (3613.HK) has released a new video showcasing its Hong Kong "Student Ambassador Programme for Chinese Medicine and Health Care", a youth engagement initiative designed to fuel young people's interest in Traditional Chinese Medicine (TCM) through fresh, hands-on, and inspiring experiences.

Rooted in BTRT's long-standing values and supported by the brand's more than 350 years of history, the programme reflects the company's commitment to promoting Chinese medicine culture while embracing innovation to connect with the next generation. Through immersive learning, 5G technology exploration and community activities, BTRT aims to make TCM more accessible, relevant and inspiring for primary and secondary school students in Hong Kong.

In the video, students share how they learned about the TCM principle of "preventive treatment of disease", discovered how herbs can support daily wellness, and gained first-hand insight into the use of Chinese medicine therapies in sports recovery.

From classroom knowledge to real-world experience One of the programme's key strengths is its ability to shape how students perceive TCM by showing its relevance to daily life, sparking curiosity, and encouraging continued conversations with peers and elders. During the visits to BTRT's Hong Kong production and R&D base, students toured the Tong Ren Tang Museum, production plant, observed the production line, and joined a hands-on workshop to experience traditional pharmaceutical craftsmanship first-hand. Students also visited BTRT's Chinese herbal garden, where they learned about the connection between Chinese medicine, nature and wellness.

Where Heritage meets Innovation and Technology The programme also introduces students to the role of innovation in modern Chinese medicine. During the visit to China Mobile 5G Innovation Centre Hong Kong Open Lab, students explored how 5G, AIoT and AI can support smarter health and wellness scenarios. Back on campus, they learned how connected sensors, communications technology and AI can be applied to Chinese herbal planting, from monitoring growth to collecting, analysing and presenting data.

Turning learning into community impact Student ambassadors also step into the community to serve as health mentors for the elderly, sharing wellness knowledge and supporting simple therapeutic activities such as Ba Duan Jin and acupoint-based care. They transform classroom learning into empathy, service and social responsibility.

Building a long-term platform for youth engagement As BTRT continues to grow in the region, the company sees youth education and cultural engagement as an important part of its long-term vision. The Student Ambassador Programme has now been extended into a long-term initiative, with this year marking its second year of rollout to nurture youngsters' interest in Chinese medicine and health care.

Following the strong response to last year's programme, it returns this year with its signature content, enhanced by the new "Campus Herbal Medicine Baizi Cabinet" initiative and visits to BTRT's herbal garden, where students can learn about the link between Chinese medicine and nature, as well as the wisdom of seasonal wellness and balance. Together, these additions extend the programme's impact, promote broader knowledge-sharing, and support the passing on of Chinese medicine culture across the campus community.

Guided by the vision of "Inheriting Traditional Chinese Medicine, Inspiring a Smarter Future," BTRT remains committed to passing on the wisdom of Chinese medicine in ways that resonate with younger generations, while contributing its unique strengths to global health development.

About Beijing Tong Ren Tang

Tong Ren Tang was founded in 1669 and has a 356-years history. The company has always adhered to its corporate motto of "No compromise on cost and labour despite the complexity of processing herbal medicine. No compromise on quality and standard despite the scarcity of medicine ingredients." This commitment has led Beijing Tong Ren Tang to steady development, lasting through every generation, achieving excellence, and becoming a national treasure while expanding globally.

At the same time, Beijing Tong Ren Tang has taken on the mission of promoting traditional Chinese medicine culture, actively participating in domestic and international traditional Chinese medicine promotion activities, facilitating cultural exchanges around the world, and striving to expand the international influence of traditional Chinese medicine. To date, it has been operating over 160 retail branches in 26 countries and regions overseas, making it one of the most recognized traditional Chinese medicine brands internationally.

The issuer is solely responsible for the content of this announcement.

Hashtags: #beijingtongrentang, #studentambassador, #TCM #traditionalChineseMedicine #BTRT

SAN DIEGO, July 21, 2026 (GLOBE NEWSWIRE) -- Axiom Biosciences, a clinical-stage biotechnology company whose lead regenerative therapy produced positive early results in newborns with severe brain injury, today announced its intention to pursue an initial public offering on the Main Board of The Stock Exchange of Hong Kong (HKEX).

The company believes the proposed listing would position it as the first U.S. biotechnology company to pursue a primary listing in Hong Kong, reflecting a broader shift in where the world's most ambitious science finds the ecosystem to thrive.

For decades, the path for a U.S. biotechnology company ran through private venture rounds and, eventually, a listing on Nasdaq or the New York Stock Exchange. Axiom is charting a different course, a primary listing in a market with deep biotechnology expertise, a strong appetite for clinical-stage innovation, and direct proximity to the Asian partners and capital already advancing Axiom's science. The company intends to pursue a secondary U.S. listing in time, building its public profile from Asia outward.

"Some of the most important science in the world is being built in the United States, but the way it gets funded hasn't kept pace," said Dr. Remo Moomiaie-Qajar, Founder and Chief Executive Officer of Axiom Biosciences. "We intend to be the first U.S. biotech to list in Hong Kong because that is where deep biotechnology capital and many of our own clinical partners increasingly are. This is about building Axiom as a global company from the start and about opening a path that other American innovators can follow."

The announcement follows a period of clinical and corporate progress. Axiom's lead regenerative therapy, developed with South Korea-based Medinno Inc., is being studied in newborns with severe intraventricular hemorrhage and hypoxic-ischemic encephalopathy, conditions with high mortality and few treatment options, and has received two U.S. FDA Rare Pediatric Disease Designations. The company's underlying platform has been supported by eight competitive research grants from U.S. federal agencies and the State of California, and Axiom is planning an expansion of the platform with a clinical trial in adult ischemic stroke, which affects roughly 700,000 Americans each year.

The timing of the proposed offering, the number of shares to be offered, and the price range have not yet been determined. The IPO is currently expected to take place in 2027, subject to regulatory review by the HKEX and the Securities and Futures Commission, prevailing market conditions, and other customary factors.

This announcement is for information purposes only and does not constitute, and shall not be construed as, an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation, or sale of securities in any jurisdiction in which such an offer, solicitation, or sale would be unlawful. Any offer of securities will be made only by means of, and subject to, a prospectus or other appropriate offering documents prepared in accordance with applicable laws and the HKEX Listing Rules.

This announcement contains forward-looking statements, including statements regarding the proposed IPO, its expected timing, and the company's strategy and clinical development plans. These statements reflect current expectations and are subject to risks and uncertainties - including regulatory review, market conditions, and the outcomes of clinical development - that could cause actual results to differ materially. Axiom undertakes no obligation to update any forward-looking statement except as required by law.

About Axiom Biosciences

Axiom Biosciences (formerly Cytonus Therapeutics) is a clinical-stage biotechnology company developing next-generation regenerative therapies and targeted biologics. Through advanced cellular engineering and translational science, the company is building a pipeline of therapies designed to address some of the most challenging diseases across neurology, inflammation, and regenerative medicine. Founded in 2018 and headquartered in San Diego, California, Axiom is advancing programs from rare pediatric conditions toward larger indications, including adult ischemic stroke. To learn more, please visit www.axiombio.co.

Media Contact

Jessica Starman

axiom@elev8newmedia.com

888-461-2233

Copyright 2026 GlobeNewswire, Inc.

Company will take no markup on humanitarian and development flows, passing through only the structural costs of each transfer

LONDON, July 21, 2026 (GLOBE NEWSWIRE) -- OpenFX, the real-time cross-border money movement platform, announced today that it will offer its cross-border FX and settlement services to humanitarian and development organizations at cost.

On qualifying NGO flows, OpenFX will charge only the structural costs of executing a transfer and will take no markup of its own. NGO flows are the first category in a broader at-cost program the company will expand over time.

Humanitarian and development organizations routinely move money through the most expensive payment corridors in the world. Aid flows are concentrated in fragile-currency markets where liquidity is thin, spreads are wide, and transfers pass through multiple intermediaries before reaching local accounts.

Because these flows are driven by crises rather than schedules, they are difficult to plan and cannot be shopped around, conditions that have historically supported significant carrier markups. A humanitarian transfer into a hard corridor can cost as much as 5 percent today, meaning $1 million lost on a $20 million relief flow before it reaches the intended recipients.

Under the new policy, OpenFX will only charge only the unavoidable costs of moving money, taking no margin on top.

"Aid money gets some of the worst prices in the world for one reason: it cannot shop around," said Prabhakar Reddy, founder and CEO of OpenFX. "A famine does not wait for three quotes, and the industry prices accordingly. We will not. On NGO flows we charge what a transfer costs, shown line by line, and take nothing on top. Every dollar taken along the way is a dollar that never becomes a food shipment or a well. Moving money through hard corridors efficiently is what we built this company to do. Removing our markup was the easiest decision we have made."

The at-cost program applies to flows from registered humanitarian and development nonprofit organizations. Eligible organizations can apply at openfx.com/impact. Verification takes days, not weeks.

OpenFX's platform settles transactions across more than 40 currency pairs, with the majority completing in under an hour, and operates continuously, including weekends and holidays, when traditional settlement systems are closed.

Press Kit: https://brandfetch.com/openfx.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/83f6bee3-ea69-467c-a351-b72f2ef9b632

Media Contact hello@openfx.com

Copyright 2026 GlobeNewswire, Inc.